Mark Tyson and Jacob Moyer discuss real-world experience with nadofarogene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer. Drawing from data across three Mayo Clinic sites, they report encouraging response rates that align with or exceed clinical trial results, including 79% complete response in CIS patients and 68% in papillary-only disease at three months. Dr. Tyson shares insights on positioning nadofarogene among available therapies, highlighting its convenience of quarterly dosing while emphasizing the importance of careful patient selection, particularly regarding the number of treatment attempts before considering more aggressive options. The discussion explores treatment durability, patient selection considerations, and the potential for retreatment in specific cases.

Biographies:

Mark Tyson II, MD, MPH, Urologic Oncologist, Mayo Clinic, Scottsdale, AZ

Jacob Moyer, BS, Medical Student, Mayo Clinic, Scottsdale, AZ

Ashish Kamat, MD, MBBS, Professor of Urology and Wayne B. Duddleston Professor of Cancer Research, University of Texas, MD Anderson Cancer Center, Houston, TX